Teva Pharmaceutical Makes Unsolicited Offer For Mylan NV

Teva Pharmaceutical Makes Unsolicited Offer For Mylan NV

Teva Pharmaceutical could make a public bid for Mylan as soon as Tuesday, in what could be the drug industry’s largest takeover attempt this year.

Play Quizzes 4

According to the latest reports, Teva proposes to acquire Mylan for $82.00 per share in cash and stock.

This Too Value Fund Explains Why Turkey Is Ripe For Investment Right Now

TurkeyThe Talas Turkey Value Fund returned 9.5% net for the first quarter on a concentrated portfolio in which 93% of its capital is invested in 14 holdings. The MSCI Turkey Index returned 13.1% for the first quarter, while the MSCI All-Country ex-USA was down 5.4%. Background of the Talas Turkey Value Fund Since its inception Read More

Teva’s buy could create a generic powerhouse

Based on a Bloomberg report, Israel-based Teva Pharmaceutical is preparing an unsolicited offer for rival Mylan NV, which has a market value of $33.3 billion. People with knowledge of the matter said besides Barclays, Teva has contacted other banks about financing a deal.

According to data compiled by Bloomberg, an all-stock offer valuing Mylan at $90 a share, representing a 30% premium to yesterday’s price, would deliver annual earnings of about $5.60 a share next year. This projection is based on an estimate by Ken Cacciatore, an analyst at Cowen Group Inc., that a combination would create $2 billion in synergies. However, the earnings gain would be even larger, if Teva could partially fund the transaction with cash or debt.

Taking the unusual step of publicly rebuking Teva’s offer in advance, Mylan said in a statement Friday that it’s not interested in a sale and doesn’t expect a potential combination to clear antitrust hurdles.

Mylan’s chairman Robert Coury said in a statement: “We have studied the potential combination of Mylan and Teva for some time and we believe it is clear that such a combination is without sound industrial logic or cultural fit. Further, there would be significant overlap in the companies’ businesses and we believe that it is unlikely that any such combination could obtain anti-trust regulatory clearances.”

Drug companies in takeover spree

The pharma sector saw an unprecedented $273 billion of deals last year as drug companies are in the midst of a takeover spree.  As reported by ValueWalk, Pfizer abandoned its takeover bid for AstraZeneca, which could have resulted in the biggest drug maker in the world.

Valeant Pharmaceuticals International also tried and failed to acquire Allergan last year.

It is felt Mylan’s unsolicited bid for Perrigo could be a trigger for Teva to act before Mylan becomes even larger. Moreover, the Israeli company had been losing market share in recent years to low-cost manufacturers such as Sun Pharmaceutical Industries Ltd. Teva is also looking for new products as a key drug faces generic competition, and acquiring Mylan would help it trim costs. The firm’s multiple sclerosis treatment Copaxone will face generic rivals this year, including possibly one produced by Mylan.

Mylan shares spiked in pre-market trading following the reports of an unsolicited offer for Mylan. Shares were up 8.8% at $74 in premarket Nasdaq trade, while Teva’s New York Stock Exchange-listed shares rose 2.9% to $65.12.

Updated on

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports
Previous article Intel Plans Itanium Chips, Maybe For The Last Time
Next article Under Armour Inc Shares Drop On Weak Full-Year Forecast

No posts to display